Metraipolis › archive › dc_af87014a03ac

Cost-Effectiveness Analysis of Recombinant Tumor Necrosis Factor Receptor: Fc Fusion Protein as First-Line Treatment for Active Rheumatoid Arthritis in China — Europe PMC PMID:41464337

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41464337
DOI
10.3390/healthcare13243267
License (as archived)
solo-consultazione
Archived
2026-11-07T16:36:04.684Z
SHA-256 of the archived text
5dc888a390501bf31a3a3b6b5e66b85990a70dbbac0b3f4ef3912418436b0c33
Stable URL of this page
https://metraipolis.com/documento/dc_af87014a03ac

How to cite

Cost-Effectiveness Analysis of Recombinant Tumor Necrosis Factor Receptor: Fc Fusion Protein as First-Line Treatment for Active Rheumatoid Arthritis in China — Europe PMC PMID:41464337 — Europe PMC (en), https://europepmc.org/article/MED/41464337 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_af87014a03ac (Metraipolis archive dc_af87014a03ac, sha256 5dc888a390501bf31a3a3b6b5e66b85990a70dbbac0b3f4ef3912418436b0c33)
BibTeX
@misc{dcaf87014a03ac,
  title = {Cost-Effectiveness Analysis of Recombinant Tumor Necrosis Factor Receptor: Fc Fusion Protein as First-Line Treatment for Active Rheumatoid Arthritis in China — Europe PMC PMID:41464337},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41464337},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_af87014a03ac; sha256 5dc888a390501bf31a3a3b6b5e66b85990a70dbbac0b3f4ef3912418436b0c33},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41464337. Agents can read the archived copy with the MCP tool read_document.